BL-918 (20, 40, or 80 mg/kg/day; oral gavage; began 2 days before the first injection of saline/MPTP and continuously maintained for 5 days after the last injection of saline/MPTP) attenuates the loss of DA and its metabolites. BL-918 obviously decreases the levels of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA)[1]. Animal Model: Male C57BL/6 mice (eight-week old) weighing between 20 and 25 g[1] Dosage: 20, 40, or 80 mg/kg Administration: Oral gavage; daily; began 2 days before the first injection of saline/MPTP and continuously maintained for 5 days after the last injection of saline/MPTP Result: Attenuated the loss of DA and its metabolites.
In Vitro
BL-918 (5 μM; for 24 hours) induces autophagy in Neuron-Like cells[1]. BL-918 (0.5-50 μM; for 24 hours) can partially reverse MPP+-induced cell death, which is determined by enhancing cell viability[1]. BL-918 (5 μM; for 6-36 hours) time-dependently elevates the expression levels of LC3-II, Beclin-1, and its phosphorylation status, whereas reduces the level of the selective autophagy substrate SQSTM1/p62. BL-918 elevates Ser317 and Ser555 phosphorylation of ULK1, as well as decreases Ser757 phosphorylation of ULK1[1]. BL-918 binds to ULK1 with a high binding affinity (KD=0.719 μM)[1]. Cell Autophagy Assay[1] Cell Line: SH-SY5Y cells Concentration: 5 μM Incubation Time: For 24 hours Result: Induced Autophagy. Cell Viability Assay[1] Cell Line: SH-SY5Y cells Concentration: 0.5, 5, 50 μM Incubation Time: For 24 hours Result: Could partially reverse MPP+-induced cell death, which was determined by enhancing cell viability. Western Blot Analysis[1] Cell Line: SH-SY5Y cells Concentration: 5 μM Incubation Time: 6, 12, 24, 36 hours Result: Time-dependently elevated the expression levels of LC3-II (a key marker of autophagy), Beclin-1, and its phosphorylation status, whereas reduced the level of the selective autophagy substrate SQSTM1/p62.
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Ouyang L, et al. Small-Molecule Activator of UNC-51-Like Kinase 1 (ULK1) That Induces Cytoprotective Autophagy for Parkinson's Disease Treatment. J Med Chem. 2018 Apr 12;61(7):2776-2792.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
